NASDAQ$IMNN
Celsion Corp · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Celsion reported first quarter 2022 financial results and provided a business update.
Celsion Corporation reported a net loss of $10.5 million, or $1.82 per share, for the first quarter of 2022. The company's operating expenses were $6.0 million, and research and development expenses were $3.1 million. Celsion had $47.3 million in cash, investments and restricted cash as of March 31, 2022, and believes it has sufficient capital resources to fund its operations into the second quarter of 2025.
- Patient enrollment in OVATION 2 continues with 85% of patients enrolled as of May 15, 2022.
- Early reports from the first thirty-nine patients showed a 27% improvement in surgical resection rate in the GEN-1 treatment arm over the control arm.
- Preclinical studies showed Celsion's next-generation PLACCINE DNA vaccine can target two different viral variants.
- BIOQUAL, Inc. is conducting a non-human primate challenge study of Celsion's vaccine candidates against SARS-CoV-2.
Headline financials
Revenue & EPS history
Celsion · Revenue · Quarterly
$125K
Forward guidance
Celsion believes it has sufficient capital resources to fund its operations into the second quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
+0.2%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+3.5%
Avg return
30 days after
32%
12 / 38 earnings
Positive
+28.7%
Q3 2019
Best reaction
-12.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.1% | -8.8% | — | |
| Q2 2025 | -4.8% | -10.3% | -28.5% | |
| Q1 2025 | +2.5% | -40.0% | +107.5% | |
| Q4 2024 | +1.2% | +6.3% | +36.2% | |
| Q3 2024 | -12.8% | -17.0% | -10.6% | |
| Q2 2024 | -0.9% | +4.6% | +1.8% | |
| Q1 2024 | +7.2% | +1.4% | -11.6% | |
| Q4 2023 | +17.1% | +25.0% | +2.9% | |
| Q3 2023 | -4.0% | -3.0% | -9.1% | |
| Q2 2023 | -3.2% | -5.6% | -10.4% | |
| Q1 2023 | -5.2% | -6.7% | +3.7% | |
| Q4 2022 | -2.3% | -6.2% | +0.8% | |
| Q3 2022 | -3.9% | -4.6% | -11.1% | |
| Q2 2022 | -1.6% | -11.6% | -19.8% | |
| Q1 2022 | +0.4% | -7.5% | -23.5% | |
| Q4 2021 | -4.5% | +17.4% | -45.3% | |
| Q3 2021 | +1.2% | -10.7% | -22.6% | |
| Q2 2021 | -1.9% | -8.4% | +0.0% | |
| Q1 2021 | +4.0% | +12.1% | +54.5% | |
| Q4 2020 | -1.3% | -22.9% | -53.3% | |
| Q3 2020 | -1.9% | -3.7% | +24.1% | |
| Q2 2020 | +0.0% | -1.8% | -28.4% | |
| Q1 2020 | -1.5% | +26.5% | +125.0% | |
| Q4 2019 | +9.0% | -3.4% | +31.5% | |
| Q3 2019 | +28.7% | +34.3% | +50.0% | |
| Q2 2019 | +0.0% | +7.1% | +3.0% | |
| Q1 2019 | +6.1% | -4.2% | -15.4% | |
| Q4 2018 | -2.5% | +19.9% | +6.5% | |
| Q3 2018 | -4.2% | -12.6% | -8.8% | |
| Q2 2018 | -9.4% | -8.7% | +2.2% | |
| Q1 2018 | -1.6% | +1.2% | +0.0% | |
| Q4 2017 | -4.3% | -11.5% | -12.6% | |
| Q3 2017 | -5.2% | -5.7% | +32.1% | |
| Q2 2017 | -1.4% | -9.5% | -5.4% | |
| Q1 2017 | +0.0% | -8.3% | -14.0% | |
| Q4 2016 | +3.4% | -3.4% | +3.4% | |
| Q3 2016 | +0.0% | -10.9% | -27.2% | |
| Q2 2016 | +4.2% | +10.0% | +3.3% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q2 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro